MiMedx Group (MDXG) Reports Q4 Loss of $0.17/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results
March 8, 2021 5:32 PM ESTFourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million
Company to Host Conference Call on March 9, 2021 at 9:30 AM ET
MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MiMedx or the Company), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced the filing of its 2020 Annual Report on Form 10-K for the period ended December 31, 2020.
Timothy R. Wright, MiMedx Chief Executive Officer, commented, 2020 was a foundational year for MiMedx, with significant accomplishments of... More
